California-based Skye Bioscience completed dosing its third cohort of eight healthy participants in its phase 1 clinical trial of SBI-100, a synthetic cannabinoid derivative designed to treat glaucoma
ONLINE ONLY: For more, see www.nzoptics.co.nz/articles/archive/vdc-tackles-choroidal-metastases
Myopia Profile, Australia’s clinical myopia-management information hub for eyecare professionals (ECPs), is aiming to transform myopia awareness into action by launching Myopia Action
ONLINE-ONLY LINKS: www.nzoptics.co.nz/articles/archive/meet-the-only-samoan-optom/
Nothing ever stays the same, especially in the world of employment law. That is particularly true now, with a host of significant changes that have recently come into effect or are imminent.
ONLINE ONLY HOTLINKS: https://www.nzoptics.co.nz/articles/archive/retina-research-review/
ONLINE ONLY - Hotlink: https://web.cvent.com/event/117e37e0-d117-4839-b367-7ec5c99431e1/summary
Pulling a crowd in the foyer of the Faculty of Medicine and Health building at the University of Auckland’s Ocular Therapeutic 2023 conference (see p36) was first-time exhibitor Zivana Anderson from Niche Pharma. She had chosen the event to launch EziDrops to New Zealand’s ophthalmic market. “The fe
In late January and early February this year, the University of Sydney ran two microsurgical courses, for the first time requiring first-year RANZCO trainees to attend. Both courses were packed with the usual corneal suturing of pigs’ eyes, EyeSi simulator time, eyelid operations on human cadavers,
Eye Health Aotearoa (EHA) and Roche New Zealand have signed a memorandum of understanding outlining how the organisations will work collaboratively for the benefit of New Zealanders’ eye health.
ONLINE-ONLY HOTLINK: www.nzoptics.co.nz/articles/archive/new-surgery-studentship-supports-w%C4%81hine/
